arrow
D

Dana B. Cardin

vanderbilt health
H指数:27
被引数:4,998

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

淋巴结靶向、mKRAS特异性的两亲性疫苗在胰腺癌中的研究:AMPLIFY-7P随机II期试验

2026-10-230
OAAI
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

I期临床试验:评估ataxia telangiectasia和Rad3-related抑制剂berzosertib联合伊立替康治疗晚期实体瘤患者的疗效(ETCTN 9938)

Cancer
IF5.1
2025-10-290
PRE
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

炎症和突变负担与nivolumab或ipilimumab联合疗法的疗效在结直肠癌中存在差异关联。

2025-10-060
OAAI
Ampullary Adenocarcinoma, Version 1.2023
2023-07-0123
OA
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

anti-OX40激动剂INCAGN01949在晚期实体瘤患者中的首次人类I/II期开放标签研究

2022-10-3137
OAAI
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
2021-12-0124
OA
Pancreatic Adenocarcinoma, Version 2.2021

胰腺腺癌2.2021版

2021-04-01597
OA
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

局部晚期直肠癌患者曲美替尼联合新辅助放化疗的I期试验

2020-07-0111
OAAI